证券代码：688606 证券简称：奥泰生物 公告编号：2023-041 杭州奥泰生物技术股份有限公司 关于调整 2022 年限制性股票激励计划 授予价格及授予数量的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 《关于<杭州奥泰生物技术股份有限公司 2022 年限制性股票激励计划实施考核 管理办法>的议案》以及《关于核查<杭州奥泰生物技术股份有限公司 2022 年限 制性股票激励计划首次授予激励对象名单>的议案》，公司监事会对本次激励计 划的相关事项进行核实并出具了相关核查意见。 公司于 2022 年 6 月 28 日在上海证券交易所网站（www.sse.com.cn）披露了 相关公告。 （二）2022 年 6 月 28 日，公司在上海证券交易所网站（www.sse.com.cn） 披露了《杭州奥泰生物技术股份有限公司关于独立董事公开征集委托投票权的公 告》（公告编号：2022-037），根据公司其他独立董事的委托，独立董事裘娟萍 女士作为征集人就 2022 年第一次临时股东大会审议的本次激励计划相关议 ...

证券代码：688606 证券简称：奥泰生物 公告编号：2023-043 杭州奥泰生物技术股份有限公司 关于作废 2022 年限制性股票激励计划 部分限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州奥泰生物技术股份有限公司（以下简称"公司"）于 2023 年 8 月 28 日 召开的第二届董事会第二十三次会议和第二届监事会第十七次会议，审议通过了 《关于<作废 2022 年限制性股票激励计划部分限制性股票>的议案》。现将有关 事项说明如下： 一、2022 年限制性股票激励计划已履行的决策程序和信息披露情况 （一）2022 年 6 月 27 日，公司召开第二届董事会第十五次会议，审议通过 了《关于<杭州奥泰生物技术股份有限公司 2022 年限制性股票激励计划（草案） 及其摘要>的议案》《关于<杭州奥泰生物技术股份有限公司 2022 年限制性股票 激励计划实施考核管理办法>的议案》及《关于提请股东大会授权董事会办理公 司 2022 年限制性股票激励计划有关事项的议案》。公司独立董事就本次激励计 划相关议案发 ...

!"#$%&'()*+,-./01 23456789:;<=+,/01 2023>?>@ABCDEFGH1 | | 督导上市公司及其董事、监事、高级管理 人员遵守法律、法规、部门规章和上海证 | 在持续督导期间，保荐机构督导奥泰生物 | | --- | --- | --- | | | | 及其董事、监事、高级管理人员遵守法律、 | | 6 | | 法规、部门规章和上海证券交易所发布的 | | | 券交易所发布的业务规则及其他规范性文 | 业务规则及其他规范性文件，切实履行其 | | | 件，并切实履行其所做出的各项承诺 | 所做出的各项承诺 | | 7 | 督导上市公司建立健全并有效执行公司治 | 保荐机构督促奥泰生物依照相关规定健全 和完善公司治理制度，并严格执行，督导 | | | 理制度，包括但不限于股东大会、董事会、 | | | | 监事会议事规则以及董事、监事和高级管 | | | | | 董事、监事、高级管理人员遵守行为规范 | | | 理人员的行为规范等 督导上市公司建立健全并有效执行内控制 | | | | 度，包括但不限于财务管理制度、会计核 算制度和内部审计制度，以及募集资金使 | 保荐机构对奥 ...

深圳价值在线咨询顾问有限公司 关于 杭州奥泰生物技术股份有限公司 2022 年限制性股票激励计划 首次授予第一个归属期 符合归属条件事项 之 独立财务顾问报告 $${\Xi}=O{\Xi}=\nwarrow\backslash\backslash\Xi$$ | | | 深圳价值在线咨询顾问有限公司 独立财务顾问报告 第一章 释 义 在本报告中，如无特殊说明，下列简称具有如下含义： | 释义项 | 释义内容 | | --- | --- | | 公司、本公司、上市公司、 指 | 杭州奥泰生物技术股份有限公司 | | 奥泰生物 | | | 限制性股票激励计划、本次 指 | 杭州奥泰生物技术股份有限公司 2022 年限制性股票激励 | | 激励计划 | 计划 | | 《激励计划（草案）》 指 | 《杭州奥泰生物技术股份有限公司 2022 年限制性股票激 | | 励计划（草案）》 | | | 本报告、本独立财务顾问报 | 《深圳价值在线咨询顾问有限公司关于杭州奥泰生物技术 | | 指 告 | 股份有限公司 2022 年限制性股票激励计划首次授予第一 | | 个归属期符合归属条件事项之独立财务顾问报告》 | | | 独立 ...

杭州奥泰生物技术股份有限公司独立董事 关于第二届董事会第二十三次会议相关事宜的独立意见 根据《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、 《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》（以下简称"《规 范运作》"）、《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》以及《杭州奥泰生物技术股份有限公司章程》（以下简称"《公司章程》"）等有 关规定，我们作为公司独立董事，认真审阅了公司第二届董事会第二十三次会议相关议 案，基于独立判断的立场，发表如下独立意见： 一、《关于<2023 年半年度募集资金存放与实际使用情况的专项报告>的议案》 经审查，我们认为，公司严格按照《规范运作》的规定，管理和使用募集资金，公 司2023年上半年募集资金的实际使用情况与《2023年半年度募集资金存放与实际使用 情况的专项报告》内容相符，不存在变相变更募集资金用途和损害股东利益的情况， 不存在违规使用募集资金等情况。 因此，我们同意公司董事会出具的《2023年半年度募集资金存放与实际使用情况 的专项报告》。 二、《关于调整 2022 年限制性股票激励计划授予价格及授予数量的 ...

证券代码：688606 证券简称：奥泰生物 公告编号：2023-038 杭州奥泰生物技术股份有限公司 关于收到公司控股股东、实际控制人、董事长提议 回购公司股份的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州奥泰生物技术股份有限公司（以下简称"公司"）于2023年8月16日收到公司 控股股东、实际控制人、董事长高飞先生《关于提议杭州奥泰生物技术股份有限公司回 购公司股份的函》。提议内容主要如下： 一、提议人提议回购股份的原因和目的 高飞先生基于对公司未来持续发展的信心和对公司价值的认可，为了维护广大 投资者利益，增强投资者对公司的投资信心，同时促进公司稳定健康发展，有效地将股 东利益、公司利益和员工个人利益紧密结合在一起，提议公司通过集中竞价交易方式进 行股份回购。回购的股份将全部用于员工持股及/或股权激励计划，并在发布股份回购 实施结果暨股份变动公告后3年内转让；若公司未能在股份回购实施结果暨股份变动公 告后3年内转让完毕，则将依法履行减少注册资本的程序，未转让股份将被注销。 二、提议人的提议内容 1、 ...

证券代码：688606 证券简称：奥泰生物 公告编号：2023-023 杭州奥泰生物技术股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2023 年 05 月 17 日(星期三)至 05 月 23 日(星期二)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 yanping.fu@alltests.com.cn 进行提问。公司将在说明会上对投资者普遍关注 的问题进行回答。 杭州奥泰生物技术股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度 经营成果、财务状况，公司计划于 2023 年 05 月 24 日下午 13:00-14:00 举行 2022 年度业绩说明会，就投资者关心的问题进行交流。 三、 参加人员 董事长、总经理：高飞 董事会秘书、财务负责人：傅燕萍 一、 说明会类型 本次投资者说明会以网络互动形式召开， ...

Financial Performance - The company's operating revenue for 2022 reached ¥3,388,568,140.41, representing an 80.88% increase compared to ¥1,873,427,739.65 in 2021[25]. - The net profit attributable to shareholders for 2022 was ¥1,184,477,646.28, a 54.69% increase from ¥765,688,919.15 in 2021[25]. - The cash flow from operating activities for 2022 was ¥1,360,685,018.85, up 47.28% from ¥923,870,826.67 in 2021[25]. - Total assets at the end of 2022 amounted to ¥4,699,723,180.82, a 17.25% increase from ¥4,008,344,382.26 at the end of 2021[25]. - The net assets attributable to shareholders increased by 27.28% to ¥4,166,522,369.83 at the end of 2022, compared to ¥3,273,637,115.17 at the end of 2021[25]. - The company reported a net profit excluding non-recurring gains and losses of ¥1,160,499,977.92 for 2022, which is a 59.14% increase from ¥729,238,275.24 in 2021[25]. - The revenue after excluding non-main business income was ¥3,387,100,388.93, also reflecting an 80.88% increase from ¥1,872,570,427.90 in 2021[25]. - The company's annual revenue increased by 80.88% compared to the previous year, driven by a 78.83% increase in COVID-19 testing products and a 93.03% increase in non-COVID-19 testing products[109]. - The gross profit margin for the in vitro diagnostic industry segment increased by 4.78 percentage points, with a gross profit margin of 59.93%[108]. - The company’s net profit increased by 54.38% compared to the same period last year, reaching 248,080,319.84 CNY[126]. Dividend and Share Capital - The company plans to distribute a cash dividend of 100 CNY per 10 shares, totaling approximately 528.68 million CNY, which represents 44.63% of the net profit attributable to shareholders[6]. - The company will increase its total share capital by 25,376,710 shares through a capital reserve transfer, raising the total share capital to 79,280,855 shares[6]. - The company’s cash dividend policy requires that cash dividends should be at least 80% for mature companies without major capital expenditures[182]. - The company’s cumulative distributable profit must be positive for cash dividends to be proposed[182]. - The company’s board of directors must provide detailed explanations if no cash dividend proposal is made despite positive profits[188]. - The company distributed a total cash dividend of ¥528,681,450, which accounts for 44.63% of the net profit attributable to ordinary shareholders in the consolidated financial statements[189]. Research and Development - The company’s R&D investment amounted to 207.30 million RMB, a 117.16% increase, accounting for 6.12% of total revenue[39]. - The total R&D investment for the year reached ¥20,729.75 million, a significant increase of 117.16% compared to the previous year[77]. - R&D investment accounted for 6.12% of total revenue, up from 5.10% in the previous year, indicating a strategic focus on innovation[77]. - The company has 32 ongoing development projects in the POCT diagnostic technology sector, with 5 projects completed[79]. - The R&D team is led by experienced professionals with over 20 years in the POCT industry, ensuring a strong foundation for future innovations[85]. - The company has developed innovative technologies such as anti-interference techniques and simplified operation methods to enhance product accuracy and market competitiveness[70]. - The company is in the R&D trial phase for new products including blood glucose dehydrogenase, blood glucose oxidase, ketone, uric acid, and cholesterol products, meeting expected performance requirements[70]. Market Presence and Strategy - The company operates under the stock code 688606 on the Shanghai Stock Exchange's Sci-Tech Innovation Board[23]. - The company is actively involved in the international market, particularly in Europe, Southeast Asia, and the Americas, to further develop key countries and markets[43]. - The company has expanded its sales network across most provinces in China, participating in regional procurement tenders and securing a presence in various medical units[42]. - The company is focusing on enhancing automation levels and transitioning to smart manufacturing through technological upgrades of existing production lines[41]. - The company has identified home diagnostic needs as a new market opportunity, driven by rising chronic disease management requirements among households[140]. - The company aims to improve internal control and management efficiency by establishing clear operational goals and optimizing management processes[143]. Corporate Governance - The company has received a standard unqualified audit report from its accounting firm[5]. - The company’s board of directors and supervisory board members have all attended the board meeting, ensuring governance compliance[5]. - The audit committee is composed of independent directors, ensuring rigorous financial oversight and compliance[166]. - The company is committed to maintaining high standards of corporate governance, as evidenced by the approval of various internal regulations and reports[163]. - The company has established specialized committees within the board to enhance strategic decision-making and oversight[166]. Risks and Challenges - The company has outlined potential risks that could significantly impact its operations in the "Management Discussion and Analysis" section[4]. - The company faces risks related to product registration, with potential delays in obtaining necessary certifications impacting market entry[93]. - The company is exposed to foreign exchange risks, with over 80% of its revenue derived from overseas sales settled in USD and EUR[100]. - The new EU regulations (IVDR) will impose stricter requirements on the company's products, potentially affecting its ODM business model and customer relationships[104]. Product Development and Innovation - The company has developed over 70 types of drug and substance abuse testing kits, making it one of the most comprehensive suppliers in this field[53]. - The company has established a POCT molecular diagnostic technology platform, integrating nucleic acid extraction, amplification, and detection processes into a compact microfluidic chip[69]. - The company has successfully developed a new generation of electrochemical biosensors, which are now being applied in multi-indicator testing products for blood glucose, ketones, uric acid, and cholesterol[70]. - The company has launched new products monthly since 2015, significantly expanding the POCT market and driving sales of conventional products[88]. - The company has achieved industrialization and mass production of its product series, significantly improving detection sensitivity[67]. Employee and Management - The company employed a total of 1,244 staff, with 1,133 in the parent company and 111 in major subsidiaries[174]. - The workforce composition includes 546 production personnel, 223 sales personnel, and 392 technical personnel[175]. - The average salary for R&D personnel rose to ¥15.53 million, up from ¥14.42 million in the previous year, reflecting the company's investment in talent[82]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 3.4987 million RMB[161]. - The company has a structured salary management system that adjusts salaries based on operational performance and industry standards[176].

Financial Performance - The company's operating revenue for Q1 2023 was CNY 236,135,335.17, representing a decrease of 88.75% compared to the same period last year[4] - The net profit attributable to shareholders for Q1 2023 was CNY 40,532,500.99, down 96.14% year-over-year[4] - Basic earnings per share for Q1 2023 were CNY 0.75, a decrease of 96.15% from the same quarter last year[4] - Total operating revenue for Q1 2023 was CNY 236,135,335.17, a decrease from CNY 2,098,917,066.48 in Q1 2022[16] - Net profit for Q1 2023 was CNY 40,336,129.33, significantly lower than CNY 1,049,121,215.40 in Q1 2022[18] - Earnings per share for Q1 2023 was CNY 0.75, compared to CNY 19.46 in Q1 2022[18] - The company reported a profit before tax of CNY 46,055,548.68 for Q1 2023, down from CNY 1,236,948,635.58 in Q1 2022[18] - The company experienced a significant reduction in sales expenses, which were CNY 16,674,929.87 in Q1 2023 compared to CNY 42,667,201.09 in Q1 2022[16] - The company reported a decrease in other income to CNY 576,469.16 in Q1 2023 from CNY 3,968,247.34 in Q1 2022[16] Cash Flow - The net cash flow from operating activities was negative CNY 177,675,720.76, reflecting a decline of 119.07% compared to the previous year[4] - Cash inflow from operating activities totaled CNY 178,230,168.16, a decrease of 91.3% compared to CNY 2,051,952,557.39 in Q1 2022[19] - Cash outflow from operating activities was CNY 355,905,888.92, down from CNY 1,120,078,405.87 in the same period last year[20] - The cash flow from operating activities showed a net outflow of CNY 162,215,506.83 in Q1 2023, compared to a net inflow of CNY 558,267,927.44 in Q1 2022[28] - Cash and cash equivalents amounted to ¥1,898,544,294.47, down from ¥1,981,842,773.82, indicating a decrease of about 4.2%[12] - Total cash and cash equivalents at the end of Q1 2023 amounted to CNY 1,869,528,440.30, down from CNY 3,057,332,086.11 at the end of Q1 2022[20] - The ending balance of cash and cash equivalents is approximately $1.46 billion, compared to $2.64 billion in the previous period[29] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,568,155,740.18, down 2.80% from the end of the previous year[5] - The company's total current assets decreased to ¥3,948,084,209.49 from ¥4,189,174,367.17, reflecting a reduction of approximately 5.8%[13] - The total liabilities decreased to CNY 350,496,292.76 in Q1 2023 from CNY 528,800,790.03 in Q1 2022[15] - The total liabilities decreased to CNY 229,573,157.02 in Q1 2023 from CNY 431,701,653.17 in Q1 2022, reflecting a reduction of approximately 46.7%[24] - The company's non-current assets totaled ¥620,071,530.69, up from ¥510,548,813.65, marking an increase of approximately 21.5%[13] - Current assets decreased to CNY 3,653,877,542.39 from CNY 3,853,352,649.30 year-over-year[23] Research and Development - Research and development expenses totaled CNY 36,121,641.21, which is a decrease of 22.89% year-over-year, but accounted for 15.30% of operating revenue, an increase of 13.07 percentage points[5] - Research and development expenses for Q1 2023 were CNY 36,121,641.21, down from CNY 46,841,374.33 in Q1 2022[16] - Research and development expenses for Q1 2023 were CNY 33,550,901.15, down from CNY 42,967,221.89 in Q1 2022, a decrease of about 21.8%[26] Shareholder Information - The top 10 shareholders collectively control 52.42% of the company’s shares, with the largest shareholder holding 23.18%[10] - The company repurchased 1,036,000 shares, representing 1.9219% of total shares, which is not included in the top 10 shareholders list[10] Other Financial Information - The company reported a non-operating income of CNY 11,656,585.11, after accounting for tax effects[6] - The company has not conducted an audit for the Q1 financial statements[4] - The company has adopted new accounting standards starting in 2023, which may affect the financial statements[29] - The report indicates that there are no adjustments made to the financial statements for the first execution year of the new accounting standards[29] - The financial report is presented by the company’s responsible person, Gao Fei, and the accounting work is overseen by Fu Yanping[29] - The report does not specify any new product developments or market expansion strategies[29] - There is no mention of mergers or acquisitions in the current financial report[29] - Future outlook and performance guidance are not detailed in the provided content[29]

2021 年半年度报告 公司代码：688606 公司简称：奥泰生物 杭州奥泰生物技术股份有限公司 2021 年半年度报告 1 / 134 2021 年半年度报告 二、重大风险提示 公司已在本报告第三节"管理层讨论与分析"的第五部分"风险因素"中说明了可能对公司 产生不利影响的风险因素，敬请投资者注意投资风险。 三、公司全体董事出席董事会会议。 六、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、前瞻性陈述的风险声明 √适用 □不适用 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 十、是否存在违反规定决策程序对外提供担保的情况？ 否 十一、是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十二、其他 □适用 √不适用 2 / 134 四、本半年度报告未经审计。 五、公司负责人高飞 、主管会计工作负责人傅燕萍 及会计机构负责人（会计 主管人员）傅燕萍声明：保证半年度报告中财务报告的真实、准确 ...